SFA Therapeutics赢得了治疗慢性肝病的第二个关键美国专利

StephenW

SFA Therapeutics Wins Second Key U.S. Patent For Treatment of Chronic Liver Diseases

Targets Liver Cancer
March 19, 2019 10:36 AM Eastern Daylight Time

JENKINTOWN, Pa.--(BUSINESS WIRE)--SFA Therapeutics today announced approval of the second key U.S. patent derived from its research & development program, which utilizes microbiome-derived metabolite small molecules as drugs to modulate the body’s anti-inflammatory and immune systems (USPTO #10,231,941).

    New drug to treat liver cancer is patented
    Tweet this

As a result of this new patent, targeting Ffar2 (GPR43) and Ffar3 (GPR441) and down-regulation of NF-ĸB, the therapeutic applications of SFA’s first major drug, SFA001, will now expand from prevention of the progression of hepatitis B to hepatocellular carcinoma (HCC- the most prevalent form of liver cancer) to direct treatment for patients afflicted with liver fibrosis, NASH, or liver cancer derived from HCC.

Commenting on the significance of this achievement, Dr. Mark Feitelson, Ph.D., Professor of Biology and Chair of the Professional Science Master's Program in Biotechnology at Temple University stated:

“Chronic hepatitis B and C infections, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD) are all associated with increased risk for the development of hepatocellular carcinoma (HCC).

In all these cases, HCC arises on a background of long-term inflammation (hepatitis) and tissue damage. HCC is the fifth most prevalent cancer and second leading cause of cancer related deaths worldwide with over 600,000 new patients diagnosed annually, most of which have a poor prognosis. Thus, there is a pressing medical need to develop new approaches to HCC prevention and treatment.

What SFA Therapeutics has done is to develop compounds from gut bacteria that have anti-inflammatory and anti-tumor activities; and demonstrate in preclinical models that these compounds significantly delay the onset of HCC in 50% of treated animals while blocking the growth of already established tumors.

Although antiviral compounds are available for patients with hepatitis B and C, nothing is available to treat most of the other patients with chronic liver diseases. SFA Therapeutics’ microbiome-derived agents represent a ‘game-changing’ new paradigm. Moreover, these compounds are nontoxic at therapeutic doses, stable, can be taken orally, and will be cost competitive, so that they will be accessible by patients in both developed and developing countries.”

About SFA Therapeutics

SFA Therapeutics is a bio-pharmaceutical company focused on new advancements in the treatment of inflammatory diseases, targeting NF-κB. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, lupus (SLE), inflammatory bowel disease (IBD), Crohn's Disease, psoriasis, liver disease and the prevention of relapse/recurrence in AML and CLL. These small-molecule drugs are derived from natural substances and enable a new platform for developing newer, safer treatments aimed at inflammatory diseases currently afflicting patients.

SFA001 has been licensed by Temple University to SFA Therapeutics in Jenkintown, PA.

Contacts

Dr. Ira C. Spector
CEO
SFA Therapeutics, Inc.
[email protected]

StephenW

SFA Therapeutics赢得了治疗慢性肝病的第二个关键美国专利

针对肝癌
2019年3月19日东部夏令时间上午10:36

宾夕法尼亚州JENKINTOWN  - （BUSINESS WIRE） - （美国商业资讯） -  SFA Therapeutics今天宣布批准第二项美国专利，该专利源于其研发计划，该计划利用微生物组衍生的代谢物小分子作为调节机体抗炎和免疫的药物。系统（USPTO＃10,231,941）。

    治疗肝癌的新药获得专利
    发推文

作为这项新专利的结果，针对Ffar2（GPR43）和Ffar3（GPR441）以及NF-ĸB的下调，SFA的第一种主要药物SFA001的治疗应用现在将从预防乙型肝炎的进展扩展到肝细胞癌（HCC-最常见的肝癌形式），用于直接治疗患有肝纤维化，NASH或源自HCC的肝癌的患者。

在评论这一成就的重要性时，Temple Feitelson博士，生物学教授和坦普尔大学生物技术专业科学硕士课程主席表示：

“慢性乙型和丙型肝炎感染，非酒精性脂肪性肝病（NAFLD），非酒精性脂肪性肝炎（NASH）和酒精性肝病（ALD）都与肝细胞癌（HCC）发病风险增加有关。

在所有这些病例中，HCC出现在长期炎症（肝炎）和组织损伤的背景下。 HCC是全球第五大流行癌症和癌症相关死亡的第二大原因，每年诊断出超过600,000名新患者，其中大多数预后不良。因此，迫切需要开发新的HCC预防和治疗方法。

SFA Therapeutics所做的是从肠道细菌中开发具有抗炎和抗肿瘤活性的化合物;并且在临床前模型中证明，这些化合物显着延迟了50％的治疗动物中HCC的发作，同时阻断了已经建立的肿瘤的生长。

虽然乙型肝炎和丙型肝炎患者可以使用抗病毒化合物，但对于大多数其他慢性肝病患者来说，没有什么可用的。 SFA Therapeutics的微生物组衍生的代理商代表了一种“改变游戏规则”的新范例。此外，这些化合物在治疗剂量下无毒，稳定，可以口服，并且具有成本竞争力，因此发达国家和发展中国家的患者都可以获得这些化合物。

关于SFA Therapeutics

SFA Therapeutics是一家生物制药公司，专注于治疗炎症性疾病的新进展，靶向NF-κB。慢性炎症涉及广泛的疾病，包括类风湿性关节炎，银屑病关节炎，狼疮（SLE），炎性肠病（IBD），克罗恩病，牛皮癣，肝病和预防AML和CLL中的复发/复发。这些小分子药物来自天然物质，为目前患病的炎症性疾病开发更新，更安全的治疗方案提供了一个新的平台。

SFA001已获得Temple大学授权给位于宾夕法尼亚州Jenkintown的SFA Therapeutics公司。

往来

Ira C. Spector博士
CEO
SFA Therapeutics，Inc。
[email protected]